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The Effects of Apigenin on Cell Proliferation and Apoptosis in Glioblastoma Multiforme 
Glioblastoma multiforme (GBM) is a WHO grade IV brain tumor. These tumors are highly 
proliferative, infiltrative, necrotic, angiogenic, and resistant to apoptosis. One major 
characteristic of GBM is the overexpression of epidermal growth factor receptor (EGFR), which 
leads to cell growth and proliferation when activated. GBM is very difficult to treat due to its 
location, heterogeneity, and invasiveness; an effective treatment is therefore needed. The use 
of flavonoids, which are natural compounds found in many fruits and vegetables, has been 
studied in the treatment of many different tumor types. Apigenin is a specific flavonoid that has 
previously been shown to have antitumor activity in a number of cancer cells. Our study set out 
to investigate the molecular effects of apigenin treatment on glioblastoma cell proliferation and 
viability using the trypan blue exclusion assay, MTT assay, and an LDH assay. In addition, 
Western blot analyses were utilized out to determine the signaling pathways through which 
apigenin treatment exerts its effects on cell proliferation and apoptosis. Finally, hoechst-
propidium iodide staining and flow cytometry were used to examine the extent of apoptosis 
and the cell cycle context of these effects. Our results show that apigenin reduces cell viability 
and proliferation in a dose and time dependent manner while increasing cytotoxicity in GBM 
cells. Additionally, apigenin inhibits the EGFR mediated phosphorylation in the presence of EGF 
treatment of AKT, mTOR, and s6k resulting in decreased cell survival, growth and proliferation. 
It also inhibits the MAPK pathways in one cell line thereby reducing cell growth and 
proliferation. It also inhibits the anti-apoptotic effects of BCL-XL and increases PARP cleavage, 
which leads to increased apoptosis. Finally, apigenin induced cycle arrest at the G2M 
checkpoint, meaning that apoptosis primarily occurred at the DNA repair checkpoint in the cell 
cycle.  In conclusion, apigenin has demonstrated some in vitro biological effects on 
glioblastoma cell lines that show promises in limiting the growth, proliferation and survival of 
these cell lines. Future research should look to identify means through which apigenin can be 
administered in clinically significant concentrations to the brain. 
